return to news
  1. Rubicon Research IPO to open on October 9: Here's a look at objectives, key dates and more

Market News

Rubicon Research IPO to open on October 9: Here's a look at objectives, key dates and more

Kamal Joshi

2 min read | Updated on October 03, 2025, 07:50 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Rubicon Research IPO: The initial share sale is a fresh issuance of shares valued at ₹500 crore and an offer for sale of ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd.

Rubicon Research is a pharmaceutical formulations company focused on research and development. | Image: rubicon.co.in

Rubicon Research is a pharmaceutical formulations company focused on research and development. | Image: rubicon.co.in

Rubicon Research IPO: The initial public offering of pharmaceutical player Rubicon Research will open for subscription from October 9 to October 13. The company has not announced the price band yet.

Open FREE Demat Account within minutes!
Join now

The initial share sale is a fresh issuance of shares valued at ₹500 crore and an offer for sale of ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd.

The funds generated will be utilised for repayment of certain outstanding borrowings availed by the company and funding inorganic growth and general corporate purposes.

Rubicon Research IPO lot size

Lot size details are yet to be announced by the company.

The company has reserved 75% of the net offer for qualified institutional buyers, 15% for non-institutional investors and the remaining 10% for retail investors.

Rubicon Research IPO timeline: Allotment and listing dates

The basis of allotment is expected to be finalised on October 14, while the refunds will be initiated on October 15. Shares will be credited to the Demat account of successful investors on the same date. Rubicon Research IPO share listing date is October 16.

Axis Capital, SBI Capital Markets, IIFL Capital Services and JM Financial are the issue's book-running lead managers, while MUFG Intime India is the registrar.

About Rubicon Research

Rubicon Research is a pharmaceutical formulations company focused on research and development, with a portfolio of speciality and drug-device combination products targeting regulated markets, especially the United States.

As of June 2025, it – directly or through its subsidiaries – collectively has 72 active abbreviated new drug applications (ANDAs) and nine new drug applications (NDAs) approved by, and one over-the-counter monograph listed with, the US FDA.

Its portfolio includes 66 commercialised products with a US general pharma market size of USD 2,455.7 million.

As of Q1 FY26, it has 17 new products pending US FDA ANDA approval and 63 products in various stages of development.

To learn more about IPOs, their listings, schedules, and upcoming IPOs, visit our page.

To add Upstox News as your preferred source on Google, click here.
SIP
Consistency beats timing.
promotion image

About The Author

Kamal Joshi
Kamal Joshi is a business journalist who covers industries, markets, and IPOs. He is passionate about breaking news and enjoys playing tennis, especially flexing his backhand. He was previously associated with Republic TV and LatestLY.

Next Story